Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases
Annals of Hematology · 2025-03 · 104 (3) · 1713-1720
DOI: 10.1007/s00277-025-06329-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Hematology, online erschienen am 03.04.2025. Verfasst von Si-Yuan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 10073…. Hauptthemen laut MEDLINE: Castleman Disease, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National High-Level Hospital Clinical Research Funding, Research and Translation Application of Beijing Clinical Diagnostic Technologies Funds from Beijing Municipal Commission of Science and Technology, Dongcheng District Outstanding Talent Nuturing Program.
Abstract (Originalsprache)
Idiopathic multicentric Castleman disease (iMCD) is a rare disease characterized by polyclonal lymphoproliferation and systemic inflammation. Siltuximab, targeting interleukin-6 (IL-6), has been recommended as the first-line therapy for iMCD. However, substantial real-world data from China were still lacking, and treatment for patients with severe iMCD remained challenging. This single-center retrospective study investigated the real-world efficacy and safety of siltuximab-based therapy in 43 consecutive patients with iMCD in China from July 2022 to March 2024. The overall response rate (including symptomatic and biochemical response) was 59% at week 3 and increased to 91% at week 12, with complete and partial response rates of 54% and 37%, respectively. Patients who received siltuximab as a first-line treatment exhibited better treatment response (OR = 0·040, 95% CI, 0·004 - 0·390, p = 0·006). Inflammatory markers (such as interleukin-6 and high-sensitivity C-reactive protein [hsCRP]) and pathologic types showed no predictive role in the treatment responses. Eighteen patients, who were all classified as severe iMCD, received combined therapy of siltuximab and BCD regimen (bortezomib, cyclophosphamide and dexamethasone). Of them, the overall response rate was 50% at week 3, which increased to 100% at week 12. Our findings reinforced the existing evidence on the efficacy and safety of siltuximab and highlighted the potential benefits of combining siltuximab with BCD regimen in severe iMCD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. pumczhanglu@126.com.
- Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. lijian@pumch.cn.
Förderung
- National High-Level Hospital Clinical Research Funding
- Research and Translation Application of Beijing Clinical Diagnostic Technologies Funds from Beijing Municipal Commission of Science and Technology
- Dongcheng District Outstanding Talent Nuturing Program
- CAMS Innovation Fund for Medical Sciences
Zitieren
APA
Li, S. Y., Gao, Y. H., Dang, Y., Chang, L., Shen, K. N., Cai, H. C., Zhao, D. Q., Wei, C., Feng, J., Zhang, L., & Li, J. (2025). Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases. Annals of Hematology, 104(3), 1713-1720. https://doi.org/10.1007/s00277-025-06329-7
Vancouver
Li SY, Gao YH, Dang Y, Chang L, Shen KN, Cai HC, et al. Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases. Annals of Hematology. 2025;104(3):1713-1720. doi:10.1007/s00277-025-06329-7
BibTeX
@article{Li2025,
author = {Li, Si-Yuan and Gao, Yu-Han and Dang, Yue and Chang, Long and Shen, Kai-Ni and Cai, Hua-Cong and Zhao, Dan-Qing and Wei, Chong and Feng, Jun and Zhang, Lu and Li, Jian},
title = {Real-world data of siltuximab for Chinese patients with iMCD: combination with BCD regimen as a potential approach for severe cases},
journal = {Annals of Hematology},
year = {2025},
volume = {104},
number = {3},
pages = {1713--1720},
doi = {10.1007/s00277-025-06329-7}
}
EUVIMED